---
title: "Weekly Recap | Zoetis +7.35%, consensus target well above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301474127.md"
description: "Zoetis rose 7.35% this week to close at $74.81, beating the S&P 500 by roughly 6.2 percentage points. The move came in two stages: Monday (5 October) opened low but climbed to $71.41, then Tuesday and Wednesday drifted near $71 before Thursday broke higher to $73.08 and Friday pushed further to end at $74.81, just off the week’s high of $74.85. The week’s range was 8.43%, with a low of $69.00."
datetime: "2026-10-10T08:12:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301474127.md)
  - [en](https://longbridge.com/en/news/301474127.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301474127.md)
generator: "portal-rs"
---

# Weekly Recap | Zoetis +7.35%, consensus target well above spot

## The Week

Zoetis rose 7.35% this week to close at $74.81, beating the S&P 500 by roughly 6.2 percentage points. The move came in two stages: Monday (5 October) opened low but climbed to $71.41, then Tuesday and Wednesday drifted near $71 before Thursday broke higher to $73.08 and Friday pushed further to end at $74.81, just off the week’s high of $74.85. The week’s range was 8.43%, with a low of $69.00.

## Key Events

This week’s news ran along two lines: heartworm data and dividends. On 6 October, Zoetis reported its own study showing Simparica Trio outperformed NexGard Plus against a resistant heartworm isolate, and a full Q2 2026 earnings call transcript also surfaced the same day. On 9 October the company declared a $0.53 per share fourth-quarter dividend, with coverage framing it as a sign of ongoing strength while some commentators kept fair value in focus. There were no major regulatory or M&A announcements during the week.

## Analyst Ratings

Across 17 covering institutions, 4 rate Zoetis a buy, 4 rate it outperform, and 9 rate it hold; none give an underperform or sell rating. The consensus recommendation is buy, with an average target of $96, about 28.3% above the last close of $74.81. Targets range from $80 to $155, a wide band that shows meaningful disagreement among analysts. Within the 203-company pharmaceutical industry rating table, Zoetis ranks 10th.

## The Week Ahead

Next Tuesday and Wednesday bring the NFIB small business optimism index, existing home sales, and October CPI and core CPI. The inflation prints may shape risk appetite across the market. Further out, Zoetis reports fiscal Q3 2026 earnings on 5 November before the open, with consensus estimates of $1.41 EPS and $2.30 billion in revenue — the next real test of the product momentum and earnings recovery seen this week.

## In Short

This week’s strength in Zoetis tracked mostly company-specific news: the resistant heartworm study added to the product narrative, while the quarterly dividend reinforced a stable cash-flow picture, and the stock closed near its weekly high alongside those headlines. On valuation, the stock trades around 11.7x earnings and 9.8x book, but the wide analyst target range suggests limited agreement on the path ahead. The next catalysts are the CPI prints and the early-November earnings report, which will show whether this week’s upward move can hold.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ZTS.US](https://longbridge.com/en/quote/ZTS.US.md)

## Related News & Research

- [Zoetis' (ZTS) Market Perform Rating Reaffirmed at William Blair](https://longbridge.com/en/news/295128765.md)
- [Zoetis Inc. $ZTS Stock Holdings Increased by Moran Wealth Management LLC](https://longbridge.com/en/news/296020852.md)
- [The AI Trade Is About to Split in Two](https://longbridge.com/en/news/302610804.md)
- [Warren Buffett's Successor, Greg Abel, Just Went Shopping in the Tech Sector Again!](https://longbridge.com/en/news/302535520.md)
- [Nebius Says It Faces Less Debt Risk Than CoreWeave As AI Spending Fears Mount](https://longbridge.com/en/news/302598593.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**